Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: Consensus on the approach to diagnosis and follow-up

JIMD Reports

Volumn 17, Issue , 2014, Pages 83-90

  van der Tol, L ^a   Cassiman, David ^b   Houge, Gunnar ^c   Janssen, Mirian C ^d   Lachmann, Robin H ^e   Linthorst, Gabor E ^a   Ramaswami, Uma ^f   Sommer, Claudia ^g   Tøndel, Camilla ^c   West, Michael L ^h   Weidemann, Frank ^g   Wijburg, Frits A ^a   Svarstad, Einar ⁱ   Hollak, Carla Em ^a   Biegstraaten, Marieke ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF BERGEN   (Norway)

Author keywords

Alternative diagnosis; Chronic kidney disease; Enzyme replacement therapy; Fabry disease; Neuropathic pain

Indexed keywords

EID: 84930639571     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2014_342     Document Type: Chapter

References (36)

1. Aerts JM, Groener JE, Kuiper S et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105(8):2812–2817
2. Bekri S, Enica A, Ghafari T et al (2005) Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron Clin Pract 101(1):c33–c38
3. Biegstraaten M, Binder A, Maag R, Hollak CE, Baron R, van Schaik IN (2011) The relation between small nerve fibre function, age, disease severity and pain in Fabry disease. Eur J Pain 15 (8):822–829
4. Biegstraaten M, Hollak CE, Bakkers M, Faber CG, Aerts JM, van Schaik IN (2012) Small fiber neuropathy in Fabry disease. Mol Genet Metab 106(2):135–141
5. Brouns R, Sheorajpanday R, Braxel E et al (2007) Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg 109(6):479–484
6. Desnick RJ, Ioannou YA, Eng CM (2007) a-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3733–3774
7. Dubuc V, Moore DF, Gioia LC, Saposnik G, Selchen D, Lanthier S (2012) Prevalence of Fabry Disease in young patients with cryptogenic ischemic stroke. J Stroke Cerebrovasc Dis 22:1288–1292
8. Elleder M, Bradova V, Smid F et al (1990) Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 417(5):449–455
9. Eng CM, Banikazemi M, Gordon RE et al (2001) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68 (3):711–722
10. Fogo AB, Bostad L, Svarstad E et al (2010) Scoring system for renal pathology in fabry disease: report of the international study group of Fabry nephropathy (ISGFN). Nephrol Dial Transplant 25:2168–2177
11. Garman SC (2007) Structure-function relationships in alpha-galactosidase A. Acta Paediatr Suppl 1802(2):247–252
12. Gold H, Mirzaian M, Dekker N et al (2013) Quantification of globotriaosylsphingosine in plasma and urine of Fabry patients by stable isotope ultraperformance liquid chromatography-tan-dem mass spectrometry. Clin Chem 59(3):547–556
13. The Human Genome Database (HGMD) (2014) www.HGMD.org
14. Hollander DA, Aldave AJ (2004) Drug-induced corneal complications. Curr Opin Ophthalmol 15(6):541–548
15. Houge G, Tondel C, Kaarboe O, Hirth A, Bostad L, Svarstad E (2011) Fabry or not Fabry–a question of ascertainment. Eur J Hum Genet 19(11):1111
16. Kobayashi M, Ohashi T, Fukuda T et al (2012) No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the alpha-galactosidase A gene. Mol Genet Metab 107(4):711–715
17. Leone O, Veinot JP, Angelini A et al (2012) 2011 consensus statement on endomyocardial biopsy from the association for European cardiovascular pathology and the society for cardiovascular pathology. Cardiovasc Pathol 21(4):245–274
18. Lin HY, Chong KW, Hsu JH et al (2009) High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2 (5):450–456
19. Lukas J, Giese AK, Markoff A et al (2013) Functional characteri-sation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet 9(8): e1003632
20. Mechtler TP, Stary S, Metz TF et al (2012) Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 379(9813):335–341
21. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281(3):249–254
22. Nakao S, Takenaka T, Maeda M et al (1995) An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med 333(5):288–293
23. Poorthuis BJ, Wevers RA, Kleijer WJ et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105 (1–2):151–156
24. Rombach SM, Dekker N, Bouwman MG et al (2010) Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta 1802 (9):741–748
25. Smid BE, Van der Tol L, Cecchi F et al (2014) Consensus recommendation on Fabry disease diagnosis in adult patients with left ventricular hypertrophy. Manuscript submitted
26. Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31–40
27. Terryn W, Vanholder R, Hemelsoet D et al (2013) Questioning the pathogenic role of the GLA p.Ala143Thr “mutation” in Fabry disease: implications for screening studies and ERT. JIMD Rep 8:101–108
28. Thurberg BL, Randolph BH, Granter SR, Phelps RG, Gordon RE, O’Callaghan M (2004) Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies. J Invest Dermatol 122(4):900–908
29. Tondel C, Bostad L, Hirth A, Svarstad E (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51(5):767–776
30. Uceyler N, He L, Schonfeld D et al (2011) Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy. J Peripher Nerv Syst 16(4):304–314
31. Uceyler N, Ganendiran S, Kramer D, Sommer C (2013) Characterization of pain in Fabry disease. Clin J Pain
32. van der Tol L, Svarstad E, Ortiz A et al (2014a) Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. Manuscript submitted
33. van der Tol L et al (2014b) Diagnosis of Fabry disease in adults with stroke and/or WMLs without characteristic signs or symptoms of Fabry disease and a genetic variant of unknown significance: a systematic review and consensus recommendation. Manuscript in preparation
34. van der Tol L, Smid BE, Poorthuis BJ et al (2014) A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 51 (1):1–9
35. Wallin EF, Clatworthy MR, Pritchard NR (2011) Fabry disease: results of the first UK hemodialysis screening study. Clin Nephrol 75 (6):506–510
36. Zampetti A, Orteu CH, Antuzzi D et al (2011) Angiokeratoma: decision making methodology for the diagnosis of Fabry disease. Br J Dermatol 166:712–720